Bloomage BioTech CEO eyes takeovers

Xuekun Jin, chief executive of the Hong Kong-listed Chinese company, talks to FinanceAsia about his plans.

Chinese cosmetics and biomedical company Bloomage BioTech, is on the lookout for acquisitions, chief executive Xuekun Jin told FinanceAsia on Thursday.

The Hong Kong-listed corporation has acquired two European businesses already, paying 59 million $63.7 million for French cosmetic device maker Vivacy in 2015 and 25.15 million for Revitacare, another French manufacturer, in January. But Jin is eager to gobble up more overseas rivals.

“We have some targets, and we’re working together with a partner,” he said, adding that the company is considering acquisitions in both Europe and the United States.

Bloomage will be helped in its search by its relationship with...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222